Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Cyclosporin¿¡ ÀÇÇØ ³ªÅ¸´Â ³ú Á¶Á÷ÀÇ Àü±âÀû º¯È­ The Change of Electrical Activity in Brain Tissue by Cyclosporin

´ëÇѼҾƽŰæÇÐȸÁö 2001³â 9±Ç 2È£ p.297 ~ 303
ÃÖº´ÁØ, À̹ÌÈñ,
¼Ò¼Ó »ó¼¼Á¤º¸
ÃÖº´ÁØ (  ) 
±¹¸³º¸°Ç¿ø ÈƷúÎ

À̹ÌÈñ (  ) 
±¹¸³º¸°Ç¿ø ÈƷúÎ

Abstract

¸ñÀû: CyclosporinÀº ¸é¿ª ¾ïÁ¦Á¦·Î¼­, ÀÓ»ó¿¡¼­ »ç¿ë½Ã Á¾Á¾ ÁßÃß ½Å°æ°è ÇÕº´Áõ Áõ¼¼°¡ ³ªÅ¸³­´Ù. Cyclosporin¿¡ ÀÇÇÑ ½Å°æ°è ÇÕº´ÁõÀÌ ¹ß»ýÇÏ´Â °ÍÀº È®½ÇÇÏÁö¸¸ ÇöÀç±îÁö Á¤È®ÇÑ ±âÀüÀº ¾Ë·ÁÁ® ÀÖÁö ¾Ê´Ù. CyclosporinÀÇ ½Å°æ°è ¿µÇâÀÌ cyclosporin´Üµ¶
È¿°úÀÎÁö ȤÀº ´Ù¸¥ ¿©·¯°¡Áö ÀÓ»óÁõ»ó°ú °ü·ÃµÇ¾î ³ªÅ¸³ª´Â °ÍÀÎÁö ºÒÈ®½ÇÇÏ´Ù. ÀÓ»ó¿¡¼­´Â Ä®½·ÀÌ ÀúÇϵǾîÀÖÀ» ¶§ »ç¿ëÇϸé ÁßÃß ½Å°æ°è ÇÕº´ÁõÀÌ ³ªÅ¸³¯ °¡´É¼ºÀÌ ¸¹Àº °ÍÀ¸·Î ³ªÅ¸³ª ÀÖ´Ù.

µû¶ó¼­, Ä®½· ÀúÇÏ»óÅ°¡ cyclosporinÀÇ ÁßÃß ½Å°æ°è¿¡ ´ëÇÑ ¿µÇâÀ» ¾Ë±â À§ÇØ µ¿¹° ½ÇÇèÀ» ÅëÇÏ¿© ¾Ë¾Æº¸¾Ò´Ù.

¹æ¹ý: ¿¬·É 14-21ÀÏ »çÀÌÀÇ Sprague-DawleyÁ㸦 ´ë»óÀ¸·Î ³ú Á¶Á÷À» °¡´ÉÇÑ »¡¸® ¾ò¾ú´Ù. À̸¦ ±ú²ýÀÌ ¾Ä°í Â÷°¡¿î »ê¼Ò ÇÔÀ¯ Àΰø ³úô¼ö¾×-NaCl 120 mM; KCl 3.3 mM; NaH2PO4 1.23 mM; MgSO4 0.9 mM; NaHCO3
25 mM;
CaCl2 2 mM; Dextrose 10 mM, pH 7.3-7.4, »ïÅõ¾Ð 315-325 mOsm/§¸ -¿¡ ³Ö°í ¼öºÐÀ» Æ÷ÇÔÇÏ°í ÀÖ´Â °¡½º(95% O2, 5% CO2)¸¦ °ø±ÞÇÑ »óÅ·Π30-45ÃÊ ³õ¾Æ µÎ¾ú´Ù. ³ú Á¶Á÷À» ²¨³»¾î ¿©°ú Á¾ÀÌ¿¡ ³õ°í Àý´ÜÇÏ¿´´Ù. ¿ÞÂÊ ³ú´Â
±ú²ýÇÏ°í
Â÷°¡¿î »ê¼Ò ÇÔÀ¯ Àΰø ³úô¼ö¾×¿¡ ³õ°í, ¿À¸¥ÂÊÀº Á¶Á÷ Àý´Ü±â (Mc Ilwain)¿¡ ³ÖÀº ÈÄ Ã³À½ 3°³ Á¶Á÷ ÀýÆíÀº ¹ö¸®°í ±× ÀÌÈÄÀÇ 3-8°³ÀÇ Á¶Á÷À» 650 §­ µÎ²²·Î Çظ¶¿¡¼­ ¾ò¾ú´Ù.

ÀÌ ÀýÆíÀ» Àú Ä®½· Àΰø ³úô¼ö¾× ¹× cyclosporin ÇÔÀ¯ ³úô¼ö¾×¿¡¼­, °¢°¢ °æ·Ã È°µ¿ º¯È­¸¦ °üÂûÇÏ¿´´Ù.

°á°ú: Ä®½· ³óµµ¿¡ µû¸¥ º¯È­´Â, Àΰø ³úô¼ö¾× ³» Ä®½· ³óµµ°¡ 1.3 mMÀÎ °æ¿ìºÎÅÍ °æ·Ã °£±â¿¡ È°µ¿ÆÄ°¡ º¸¿³´Âµ¥ 1.3 mMÀÎ °æ¿ì °æ·Ã °£±â È°µ¿Àº 18.8%¿¡¼­ º¸¿´°í, Ä®½· ³óµµ°¡ 0.8 mMÀÎ °æ¿ì °£Áú °£±â È°µ¿Àº 41.7%¿¡¼­ º¸¿´À¸¸ç, Ä®½· ³óµµ°¡ 0 mMÀÎ
°æ¿ì
°æ·Ã È°µ¿Àº 60%¿¡¼­ º¸ÀÌ°í °æ·Ã °£±â È°µ¿ÀÌ ¸ðµÎ ³ªÅ¸³µ´Ù.

Cyclosporin 3 §­ óġ ³ú Á¶Á÷¿¡¼­ °æ·Ã °£±â È°µ¿Æĸ¦ °üÂûÇÒ ¼ö ÀÖ´Ù. °æ·Ã °£±â È°µ¿ÆÄÀÇ Æò±Õ ½Ã°£°ú ¼ö´Â 116.4¡¾44.4 ÃÊ, 63.6¡¾35.8 À̾ú´Ù. °æ·Ã °£±â È°µ¿ÆÄÀÇ ½Ã°£°ú ¼ö´Â ´ëÁ¶±º°ú ºñ±³ÇÏ¿© Å« Â÷ÀÌ´Â ¾ø¾ù´Ù. °æ·Ã °£±â È°µ¿ÆÄ°¡ ³ªÅ¸³¯ ¶§±îÁö Àẹ
½Ã°£Àº
166.2¡¾29.8 ÃÊ¿´´Ù.

°á·Ð: º» ¿¬±¸ °á°ú ³úô¼ö¾×ÀÇ Ä®½· ³óµµ°¡ 1.3 §­ ³óµµ¿¡¼­ºÎÅÍ cyclosporinÀÌ °æ·Ã È°µ¿À» Áõ°¡½ÃÅ°´Â °ÍÀ» ¾Ë ¼ö ÀÖ¾ú´Ù. µû¶ó¼­, cyclosporinÀº ȯÀÚÀÇ ¿©·¯ °¡Áö ÀÓ»ó »óÅ¿¡ µû¶ó ÁßÃß ½Å°æ°è µ¶¼ºÀ» ³ªÅ¸³¾ ¼ö ÀÖ°í, ƯÈ÷ Ä®½·ÀÌ ÀúÇÏµÈ È¯ÀÚ
»óÅ¿¡¼­
cyclosporin »ç¿ëÀº ÇÇÇÏ¿©¾ß Çϸç, ÇÇÄ¡ ¸øÇØ »ç¿ëÇÏ¿©¾ß ÇÒ °æ¿ì¿¡´Â ÁßÃß ½Å°æ°èÀÇ ÇÕº´Áõ¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ °üÂûÀÌ µ¿¹ÝµÇ¾î¾ß ÇÑ´Ù°í »ý°¢ÇÑ´Ù.

Purpose: Cyclosporin is used in children with immune-mediated diseases, chronic disease, organ transplantation, or malignancy. These diseases often require a higher dose of cyclosporin, and cyclosporin displayed neurotoxicity of the
central
nervous system (CNS) neurotoxicity. Especially, cyclosporin-induced seizures often represent a physical threat to patients. And, the adverse effects of cyclosporin on CNS are considered.

Methods: The study was done with Sprague-Dawley rats(14-21 days), weighting from 28.7 g to 49.2 g. The animal were kept in-groups with mother rat in cages, and had free access to food and tap water. The temperature of the animal room is
room
temperature. Hippocampal slices were taken. Hippocampal slices were exposed to cyclosporin dissolved by 0.1% DMSO(Dimethyl sulfoxide). Then, we began to record electrical activity of slices every 10 minutes in low calcium environment. We observed
the
frequency and duration of electrical activity.

Results: The mean duration and frequency of cyclosporin 3M-treated ictal activity was 35.51.4 seconds and 133.017.9. These results were significantly different compared to the control group. The mean duration and frequency in cyclosporin
3M-treated interictal activity was 116.444.4 seconds, 63.635.8. There were no significant differences in the duration and frequency of onset in cyclosporin 3M-treated interictal activity compared with control showing interictal activity. The mean
duration of latency time of onset in cyclosporin 3M-treated interictal activity was 166.229.8 seconds(n=9), and there was a significant difference in the latency of onset time in cyclosporin 3M-treated interictal activity compared with control
showing
interictal activity.

Conclusion: Although cyclosporin neurotoxicity is well recognized, and the exact mechanism of cyclosporin neurotoxicity is still unclear, cyclosporin neurotoxicity is present under hypocalcemia. And, our results suggest that careful usage
of
cyclosporin in clinical conditions with hypocalcemia is required to avoid cyclosporin neurotoxicity.

Å°¿öµå

Cyclosporin; CNS;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS